Valuation: Relay Therapeutics, Inc.

Market Cap 4.06B 3.57B 3.32B 3.05B 5.72B 388B 5.82B 39.39B 15.42B 192B 15.25B 14.92B 665B P/E 2026 *
-12.1x
P/E 2027 * -11.8x
Enterprise Value 3.77B 3.31B 3.08B 2.83B 5.31B 360B 5.4B 36.56B 14.31B 179B 14.15B 13.85B 617B EV / Sales 2026 *
319x
EV / Sales 2027 * 265x
Free-Float
93.64%
Yield 2026 *
-
Yield 2027 * -
1 day-3.06%
1 week-6.40%
Current month-3.45%
1 month-8.49%
3 months+38.64%
6 months+136.14%
Current year+113.53%
1 week 17.71
Extreme 17.71
19.51
1 month 17.67
Extreme 17.67
20.79
Current year 7.01
Extreme 7.01
20.79
1 year 3.02
Extreme 3.025
20.79
3 years 1.78
Extreme 1.775
20.79
5 years 1.78
Extreme 1.775
38.15
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2017
Director of Finance/CFO 49 01/04/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 04/05/2015
Director/Board Member 66 01/07/2016
Director/Board Member 52 01/03/2017
Date Insider Type Main position Quantity % Market Cap.
07/07/26 Sell

Chief Executive Officer

-48,199 0.0221%
06/07/26 Sell

Chief Technology Officer

-8,660 0.0040%
06/07/26 Sell

Chief Financial Officer

-17,717 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
-3.03%-6.40%+388.24%+47.77% 4.06B
+0.14%-0.67%-0.88%+11.02% 47.74B
-3.43%-0.81%+387.95%+607.16% 39.98B
+0.60%+2.82%+11.26%+45.55% 36.23B
+11.27%+17.59%+19.89%+4.84% 35.59B
-0.73%+2.78%+4.65%+41.16% 27.91B
-1.76%-2.74% - - 16.71B
-2.39%+8.43%+27.25%+126.24% 16.45B
+2.39%-1.64%+4.74%+9.95% 13.21B
+6.87%+8.06%-5.07%-28.59% 12.93B
Average +1.02%+2.22%+93.11%+96.12% 25.08B
Weighted average by Cap. +1.31%+2.86%+80.04%+127.31%

Financials

2026 *2027 *
Net sales 11.8M 10.36M 9.65M 8.87M 16.63M 1.13B 16.92M 114M 44.8M 559M 44.32M 43.36M 1.93B 14.5M 12.73M 11.85M 10.9M 20.43M 1.39B 20.78M 141M 55.03M 687M 54.44M 53.26M 2.37B
Net income -292M -256M -239M -220M -412M -27.92B -419M -2.83B -1.11B -13.85B -1.1B -1.07B -47.84B -312M -274M -255M -235M -440M -29.82B -447M -3.03B -1.18B -14.79B -1.17B -1.15B -51.09B
Net Debt -292M -256M -239M -220M -411M -27.9B -419M -2.83B -1.11B -13.84B -1.1B -1.07B -47.8B -221M -194M -180M -166M -311M -21.1B -317M -2.14B -838M -10.46B -829M -811M -36.15B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
193
Date Price Change Volume
28/07/26 $18.05 -3.19% 971,308
27/07/26 $18.64 +1.08% 4,202,088
24/07/26 $18.44 -3.40% 2,039,977
23/07/26 $19.09 -0.93% 1,241,745
22/07/26 $19.27 -0.16% 1,321,209
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
18.64USD
Average target price
26.08USD
Spread / Average Target
+39.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock